Lauren Silverman
Signal active
Managing Director
Bio
Lauren Silverman is a Managing Director in Cambridge, MA, USA.
Prior to joining NVF, she was Global Head of Oncology Research Operations for Novartis Institutes for Biomedical Research, and Director of Business Development and Licensing at Pfizer and OSI Pharmaceuticals. Lauren was a founding scientist of Cadus Pharmaceuticals.
Lauren earned her PhD in molecular biology from the University of Utah, followed by fellowships at Princeton and Memorial Sloan Kettering.
Lauren serves on the Boards of Celladon, Pulmatrix Inc., Proteostasis Therapeutics, Ra Pharmaceuticals and Viamet Pharmaceuticals.
Location
Boston, Massachusetts, United States, North America
Social
Primary Organization
Novartis Venture Fund
Founded
1996
Investment
256
Lead investment
70
Exits
71
Employees
11-50
Industry
Venture Capital, Finance, Therapeutics
Jobs history
0
N/A
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Lauren Silverman is the Managing Director at Novartis Venture Fund, based in United States, North America. With a background in Venture Capital, Lauren Silverman has a rich history of leadership and innovation. Lauren Silverman studied Ph.D Molecular Biology @ University of Utah. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
N/A
Number of investment
1
Number of exits
0
Personal investment
0
There is no personal investment available on this profile
Partner investment
4
| Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
|---|---|---|---|---|
| Aug 15, 2011 | Pulmatrix | Series B - Pulmatrix | Novartis Venture Fund | 14.0M |
| Feb 15, 2012 | Celladon | Venture Round - Celladon | Novartis Venture Fund | 43.0M |
| Oct 21, 2014 | - | Series D - Viamet Pharmaceuticals | Novartis Venture Fund | 60.0M |
| Sep 08, 2015 | Proteostasis Therapeutics | Series B - Proteostasis Therapeutics | Novartis Venture Fund | 37.0M |
Pulmatrix
Novartis Venture Fund
Celladon
Proteostasis TherapeuticsExits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.